Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Release Date: August 29, 2025

Expiration Date: August 29, 2026

Activity Overview

Psoriasis (PsO) is a chronic, systemic inflammatory disease that affects 3% of US adults; it has been increasingly prevalent over the past years. The disorder is often characterized by chronicity, high grade of disability, and related comorbidities. Notably, biologic agents targeting the interleukin (IL)-23/IL-17 axis have demonstrated improved efficacy compared with conventional therapies and include several FDA-approved agents.

This case-based continuing education program is intended to increase clinician knowledge of the key therapeutic targets within the IL-23/IL-17 pathway and the role of biologic agents directed against these key targets in managing PsO, including in difficult-to-treat areas. The mechanisms of action, efficacy, safety, and limitations of these agents are discussed, as well as methods to identify patients who would optimally benefit from these targeted biologic therapies.

This educational activity is an archive of the live virtual symposium held on July 26, 2025.

Target Audience

This educational activity is directed toward dermatology nurse practitioners, physician assistants, and other health care providers involved in managing PsO.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply recommended eligibility criteria to determine patients appropriate for anti–IL-17 and anti–IL-23 biologic therapies based on disease severity of PsO
• Evaluate safety and efficacy data for approved anti–IL-17 and anti–IL-23 biologic agents directed against key treatment targets within the IL-23/IL-17 inflammatory pathway for managing PsO
• Develop holistic, individualized management plans for patients with PsO that incorporate anti–IL-17 or anti–IL-23 biologic therapy based on patient-specific needs and shared goals of therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.